Patents by Inventor Jae-hung Shieh

Jae-hung Shieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of Ureidomustine (BO-1055) in Cancer Treatment
    Publication number: 20200246284
    Abstract: Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of small lung cell carcinoma (SCLC).
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Inventors: Malcolm Moore, Jae-Hung Shieh, Tsann-Long Su, Te-Chang Lee
  • Use of ureidomustine (BO-1055) in cancer treatment
    Patent number: 10548861
    Abstract: Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 4, 2020
    Assignees: Academia Sinica, Memorial Sloan Kettering Cancer Center
    Inventors: Malcolm Moore, Jae-Hung Shieh, Tsann-Long Su, Te-Chang Lee
  • Use of Ureidomustine (BO-1055) in Cancer Treatment
    Publication number: 20190008808
    Abstract: Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
    Type: Application
    Filed: August 17, 2016
    Publication date: January 10, 2019
    Inventors: Malcolm Moore, Jae-Hung Shieh, Tsann-Long Su, Te-Chang Lee
  • HOMOGENOUS AND FULLY GLYCOSYLATED HUMAN ERYTHROPOIETIN
    Publication number: 20130323774
    Abstract: The present invention provides homogenous, fully-glycosylated, full length erythropoietin and the methods of producing the same.
    Type: Application
    Filed: April 30, 2013
    Publication date: December 5, 2013
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Ping Wang, Suwei Dong, Malcolm Andrew Stephen Moore, Jae-hung Shieh, John Andrew Brailsford